{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:06:45Z","timestamp":1779361605915,"version":"3.51.4"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have substantially improved outcomes in advanced melanoma but are frequently linked to immune-related adverse events (irAEs). Vitiligo is a common cutaneous irAE and has been consistently associated with improved patient outcome, including prolonged progression-free and overall survival. It also represents significant visual stigma, particularly when the face is involved. Traditional treatment comprises topical steroids, calcineurin inhibitors, laser, and phototherapy which often have insufficient effects. Since 2023, the first approved drug for non-segmental vitiligo (NSV) with facial involvement, the topical Janus kinase inhibitor ruxolitinib, has been available. However, experience with its use in ICI-induced vitiligo remains limited. In this exploratory analysis, three patients who developed facial vitiligo following ICI therapy applied 1.5% ruxolitinib cream to affected facial areas twice daily. After six (two patients), and twelve months (one patient), extensive repigmentation was observed, quantified at 95.7%, 78.9%, and 99.1% using a novel semi-automatic tool. Quality-of-life questionnaires showed mean reductions of 57.6% (Vitiligo DLQI) and 68.2% (Vitiligo-specific Quality of Life) in disease burden. Treatment was associated with substantial repigmentation without observed side effects. Further evaluation in larger, prospective cohorts is warranted to better define treatment effects, clinical applicability, and long-term safety.<\/jats:p>","DOI":"10.3390\/curroncol33050300","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:29:58Z","timestamp":1779355798000},"page":"300","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool"],"prefix":"10.3390","volume":"33","author":[{"given":"Thomas","family":"Breakell","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0730-0893","authenticated-orcid":false,"given":"Paolo","family":"Neri","sequence":"additional","affiliation":[{"name":"Department of Civil and Industrial Engineering, University of Pisa, 56122 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onie A. N.","family":"Staats","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-6489","authenticated-orcid":false,"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN and CCC Alliance WERA, 91054 Erlangen, Germany"},{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF), 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref_1","first-page":"119","article-title":"Checkpoint Inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Watanabe, T., and Yamaguchi, Y. (2023). Cutaneous Manifestations Associated with Immune Checkpoint Inhibitors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1071983"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1038\/s41598-022-11128-5","article-title":"Cutaneous Immune-Related Adverse Events among Taiwanese Cancer Patients Receiving Immune Checkpoint Inhibitors Link to a Survival Benefit","volume":"12","author":"Cho","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Curkovic, N.B., Bai, K., Ye, F., and Johnson, D.B. (2024). Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16020340"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2016.07.060","article-title":"Melanoma-Associated Leukoderma and Vitiligo Cannot Be Differentiated Based on Blinded Assessment by Experts in the Field","volume":"75","author":"Lommerts","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1610-0387.2008.06755.x","article-title":"Vitiligo and Melanoma-associated Hypopigmentation (MAH):Shared and Discriminative Features","volume":"6","author":"Hartmann","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e22023","DOI":"10.1200\/JCO.2020.38.15_suppl.e22023","article-title":"Vitiligo Is Correlated with Clinical Benefits in Patients with Advanced Cutaneous Melanoma Treated with Immune Checkpoint Inhibitors (ICI)","volume":"38","author":"Muino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jdin.2021.09.002","article-title":"Analysis of Tumor Response and Clinical Factors Associated with Vitiligo in Patients Receiving Anti\u2013Programmed Cell Death-1 Therapies for Melanoma: A Cross-Sectional Study","volume":"5","author":"Dousset","year":"2021","journal-title":"JAAD Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo Is an Independent Favourable Prognostic Factor in Stage III and IV Metastatic Melanoma Patients: Results from a Single-Institution Hospital-Based Observational Cohort Study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under Anti-Programmed Cell Death-1 Therapy Is Associated with Increased Survival in Melanoma Patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between Vitiligo Occurrence and Clinical Benefit in Advanced Melanoma Patients Treated with Nivolumab: A Multi-Institutional Retrospective Study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo with Tumor Response in Patients with Metastatic Melanoma Treated with Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like Depigmentation in Patients with Stage III-IV Melanoma Receiving Immunotherapy and Its Association with Survival: A Systematic Review and Meta-Analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2023316S","DOI":"10.5826\/dpc.1304S2a316S","article-title":"Vitiligo: Unmet Need, Management and Treatment Guidelines","volume":"13","author":"Marzano","year":"2023","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","article-title":"JAK Inhibitors for the Treatment of Vitiligo","volume":"113","author":"Inoue","year":"2024","journal-title":"J. Dermatol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jdin.2024.10.005","article-title":"Association of Vitiligo with Immune-Checkpoint Inhibitor Therapy: A Systematic Review","volume":"18","author":"Fleshner","year":"2025","journal-title":"JAAD Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/curroncol31020083","article-title":"Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center","volume":"31","author":"Coelho","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2024.5136","article-title":"Immune Checkpoint Inhibitor-Induced Vitiligo-like Depigmentation","volume":"161","author":"Starace","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jdv.20321","article-title":"The Dermatology Life Quality Index (DLQI) Used as the Benchmark in Validation of 101 Quality-of-Life Instruments: A Systematic Review","volume":"39","author":"Vyas","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","article-title":"Development and Validation of a Vitiligo-Specific Quality-of-Life Instrument (VitiQoL)","volume":"69","author":"Lilly","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","first-page":"25","article-title":"Revealing The Unseen: A Review of Wood\u2019s Lamp in Dermatology","volume":"15","author":"Dyer","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2021.06.880","article-title":"Development and Validation of the Fingertip Unit for Assessing Facial Vitiligo Area Scoring Index","volume":"86","author":"Bae","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Neri, P., Fiaschi, M., and Menchini, G. (2020). Semi-Automatic Tool for Vitiligo Detection and Analysis. J. Imaging, 6.","DOI":"10.3390\/jimaging6030014"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zuiderveld, K. (1994). Contrast Limited Adaptive Histogram Equalization. Graphics Gems IV, Academic Press Professional, Inc.","DOI":"10.1016\/B978-0-12-336156-1.50061-6"},{"key":"ref_27","unstructured":"(2026, May 15). Adapthisteq\u2013Contrast-Limited Adaptive Histogram Equalization (CLAHE)\u2013MATLAB. Available online: https:\/\/www.mathworks.com\/help\/images\/ref\/adapthisteq.html."},{"key":"ref_28","unstructured":"Amin, M.B., and Edge, S.B. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_29","unstructured":"(2026, May 15). Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0; Published: 27 November 2017, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial Effects of Vitiligo: A Systematic Literature Review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo Prevalence and Quality of Life among Adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bissonnette, R., Saint-Cyr Proulx, E., Correa da Rosa, J., Estrada, Y., Ren, H., Nawaz, H., Halden, P., Stefani-Hunyady, D., Popovic, K., and Volkova, A. (J. Investig. Dermatol., 2025). Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated with Biomarkers, J. Investig. Dermatol., in press.","DOI":"10.1016\/j.jid.2025.10.613"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_34","unstructured":"Moore, R.A., Popowicz, P., and Burns, B. (2025). Rule of Nines. StatPearls, StatPearls Publishing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide Expert Recommendations for the Diagnosis and Management of Vitiligo: Position Statement from the International Vitiligo Task Force-Part 2: Specific Treatment Recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/300\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:27:27Z","timestamp":1779359247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050300"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050300","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}